{"title":"粪肠球菌129 BIO 3B被归类为乳酸肠球菌129 BIO 3B。","authors":"Kiyofumi Ohkusu","doi":"10.12938/bmfh.2022-088","DOIUrl":null,"url":null,"abstract":"<p><p><i>Enterococcus faecium</i> 129 BIO 3B is a lactic acid bacterium that has been safely used as a probiotic product for over 100 years. Recently, concerns about its safety have arisen because some species of <i>E. faecium</i> belong to the vancomycin-resistant enterococci. The groups of <i>E. faecium</i> with less pathogenic potential have been split into a separate species (<i>Enterococcus lactis</i>). In this study, I investigated the phylogenetic classification and safety of <i>E. faecium</i> 129 BIO 3B as well as <i>E. faecium</i> 129 BIO 3B-R, which is naturally resistant to ampicillin. Mass spectrometry and basic local alignment search tool analysis using specific gene regions failed to differentiate 3B and 3B-R into <i>E. faecium</i> or <i>E. lactis</i>. However, multilocus sequence typing successfully identified 3B and 3B-R as the same sequence types as <i>E. lactis</i>. Overall genome relatedness indices showed that 3B and 3B-R have high degrees of homology with <i>E. lactis</i>. Gene amplification was confirmed for 3B and 3B-R with <i>E. lactis</i> species-specific primers. The minimum inhibitory concentration of ampicillin was confirmed to be 2 µg/mL for 3B, which is within the safety standard for <i>E. faecium</i> set by the European Food Safety Authority. Based on the above results, <i>E. faecium</i> 129 BIO 3B and <i>E. faecium</i> 129 BIO 3B-R were classified as <i>E. lactis</i>. The absence of pathogenic genes except for <i>fms21</i> in this study demonstrates that these bacteria are safe for use as probiotics.</p>","PeriodicalId":8867,"journal":{"name":"Bioscience of Microbiota, Food and Health","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/70/bmfh-42-180.PMC10315194.pdf","citationCount":"0","resultStr":"{\"title\":\"<i>Enterococcus faecium</i> 129 BIO 3B is classified as <i>Enterococcus lactis</i> 129 BIO 3B.\",\"authors\":\"Kiyofumi Ohkusu\",\"doi\":\"10.12938/bmfh.2022-088\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><i>Enterococcus faecium</i> 129 BIO 3B is a lactic acid bacterium that has been safely used as a probiotic product for over 100 years. Recently, concerns about its safety have arisen because some species of <i>E. faecium</i> belong to the vancomycin-resistant enterococci. The groups of <i>E. faecium</i> with less pathogenic potential have been split into a separate species (<i>Enterococcus lactis</i>). In this study, I investigated the phylogenetic classification and safety of <i>E. faecium</i> 129 BIO 3B as well as <i>E. faecium</i> 129 BIO 3B-R, which is naturally resistant to ampicillin. Mass spectrometry and basic local alignment search tool analysis using specific gene regions failed to differentiate 3B and 3B-R into <i>E. faecium</i> or <i>E. lactis</i>. However, multilocus sequence typing successfully identified 3B and 3B-R as the same sequence types as <i>E. lactis</i>. Overall genome relatedness indices showed that 3B and 3B-R have high degrees of homology with <i>E. lactis</i>. Gene amplification was confirmed for 3B and 3B-R with <i>E. lactis</i> species-specific primers. The minimum inhibitory concentration of ampicillin was confirmed to be 2 µg/mL for 3B, which is within the safety standard for <i>E. faecium</i> set by the European Food Safety Authority. Based on the above results, <i>E. faecium</i> 129 BIO 3B and <i>E. faecium</i> 129 BIO 3B-R were classified as <i>E. lactis</i>. The absence of pathogenic genes except for <i>fms21</i> in this study demonstrates that these bacteria are safe for use as probiotics.</p>\",\"PeriodicalId\":8867,\"journal\":{\"name\":\"Bioscience of Microbiota, Food and Health\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/70/bmfh-42-180.PMC10315194.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bioscience of Microbiota, Food and Health\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12938/bmfh.2022-088\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Agricultural and Biological Sciences\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioscience of Microbiota, Food and Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12938/bmfh.2022-088","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}
引用次数: 0
摘要
粪肠球菌129 BIO 3B是一种乳酸菌,作为益生菌产品已经安全使用了100多年。最近,由于某些种类的粪肠球菌属于万古霉素耐药肠球菌,人们对其安全性产生了担忧。致病性较低的粪肠球菌群被分成一个单独的种(乳酸肠球菌)。在本研究中,我研究了E. faecium 129 BIO 3B和E. faecium 129 BIO 3B- r的系统发育分类和安全性,其中E. faecium 129 BIO 3B- r对氨苄西林具有天然耐药性。质谱分析和使用特定基因区域的基本局部比对搜索工具无法将3B和3B- r区分为E. faecium或E. lacactis。然而,多位点序列分型成功地鉴定出3B和3B- r与E. lactis为相同的序列类型。总体基因组关联指数显示,3B和3B- r与乳杆菌具有高度同源性。用乳杆菌种特异性引物扩增3B和3B- r基因。确认氨苄青霉素对3B的最低抑菌浓度为2µg/mL,符合欧洲食品安全局制定的粪肠杆菌安全标准。基于以上结果,将E. faecium 129 BIO 3B和E. faecium 129 BIO 3B- r归类为乳杆菌。本研究中除fms21外未发现致病基因,表明这些细菌作为益生菌是安全的。
Enterococcus faecium 129 BIO 3B is classified as Enterococcus lactis 129 BIO 3B.
Enterococcus faecium 129 BIO 3B is a lactic acid bacterium that has been safely used as a probiotic product for over 100 years. Recently, concerns about its safety have arisen because some species of E. faecium belong to the vancomycin-resistant enterococci. The groups of E. faecium with less pathogenic potential have been split into a separate species (Enterococcus lactis). In this study, I investigated the phylogenetic classification and safety of E. faecium 129 BIO 3B as well as E. faecium 129 BIO 3B-R, which is naturally resistant to ampicillin. Mass spectrometry and basic local alignment search tool analysis using specific gene regions failed to differentiate 3B and 3B-R into E. faecium or E. lactis. However, multilocus sequence typing successfully identified 3B and 3B-R as the same sequence types as E. lactis. Overall genome relatedness indices showed that 3B and 3B-R have high degrees of homology with E. lactis. Gene amplification was confirmed for 3B and 3B-R with E. lactis species-specific primers. The minimum inhibitory concentration of ampicillin was confirmed to be 2 µg/mL for 3B, which is within the safety standard for E. faecium set by the European Food Safety Authority. Based on the above results, E. faecium 129 BIO 3B and E. faecium 129 BIO 3B-R were classified as E. lactis. The absence of pathogenic genes except for fms21 in this study demonstrates that these bacteria are safe for use as probiotics.
期刊介绍:
Bioscience of Microbiota, Food and Health (BMFH) is a peer-reviewed scientific journal with a specific area of focus: intestinal microbiota of human and animals, lactic acid bacteria (LAB) and food immunology and food function. BMFH contains Full papers, Notes, Reviews and Letters to the editor in all areas dealing with intestinal microbiota, LAB and food immunology and food function. BMFH takes a multidisciplinary approach and focuses on a broad spectrum of issues.